SEC Tracker
Get the app
PBYI · XBRL financial data

Puma Biotechnology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PBYI's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers5672*44478159*46525475*4557
Cost of goods and services sold1324*11112914*11121223*1012
Selling, general and administrative2320*22251717*18181718*1818
Operating income (loss)915*(2)(2)2213*471017*(4)8
Interest income11*1111*1111*11
Interest expense33*3333*2211*10
Other income (expense)01*0000*0000*00
Income tax expense (benefit)01*000(7)*———year only——
Net income (loss)612*(5)(5)2019*36913*(4)8
Earnings per share, basic USD per share0.120.26*(0.10)(0.09)0.410.39*0.060.120.180.27*(0.07)0.16
Earnings per share, diluted USD per share0.120.26*(0.10)(0.09)0.410.38*0.060.120.170.26*(0.07)0.16
Weighted average shares, basic millions of shares4848*48484949*50505050*5151
Weighted average shares, diluted millions of shares4848*48484951*50505152*5153

Balance sheet

CSV

Fiscal quarters (PBYI's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents828577676769635554303637
Marketable securities31130302932304141686557
Accounts receivable294825285532252634542634
Inventory6779399996913
Total current assets125156143138157148133137144163142145
Property and equipment, net111111000000
Right-of-use asset987655436554
Total assets204231214205221213196195203216193193
Accounts payable5791486656583
Accrued liabilities345338395137273237503845
Current portion of long-term debt23344545454545343423110
Total current liabilities67999810411096877983816050
Long-term debt77665544332211110000
Lease liability, non-current876431005554
Total liabilities165177163156150121999088866454
Accumulated deficit(1,357)(1,345)(1,350)(1,355)(1,334)(1,315)(1,312)(1,306)(1,297)(1,284)(1,288)(1,279)
Total stockholders' equity39535149719297105115130128139
Total liabilities and equity204231214205221213196195203216193193
Common shares outstanding (cover page) millions of shares484848494950505050515152

Cash flows

CSV

Fiscal quarters (PBYI's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)612*(5)(5)2019*36913*(4)8
Stock-based compensation3*2*22*2*2*22*2*2*22*
Net cash from operating activities11*10*111*11*16*414*10*14*152*
Purchases of property and equipment0*0*00*0*0*00*0*(0)*00*
Net cash from investing activities11*(8)*(19)1*0*(2)*2(11)*1*(27)*28*
Net cash from financing activities0*0*0(11)*(11)*(11)*(11)(11)*(11)*(11)*(11)(11)*
Net change in cash22*2*(8)(10)*0*2*(6)(8)*(1)*(24)*7(2)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Puma Biotechnology37571.6*51.6M— 10-QJun 30, 2026
Eledon Pharmaceuticals6.8not reported(23)*81.3M3.9 quarters 10-QJun 30, 2026
Neurogene112not reported(24)*20.0M9.5 quarters 10-QJun 30, 2026
Voyager Therapeutics363.2(26)*61.6M4.5 quarters 10-QJun 30, 2026
Aclaris Therapeutics191.6(20)*147.2M4.6 quarters 10-QJun 30, 2026
Alpha Cognition416.1(6.9)*21.8M6.0 quarters 10-QJun 30, 2026
Sangamo Therapeutics281.4(19)414.3M1.4 quarters 10-QMar 31, 2026
Vistagen Therapeutics17not reported(15)44.4M2.2 quarters 10-QJun 30, 2026
Monopar Therapeutics530*(3.2)*6.7M32.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.